[1] ZHAO H Y, WEI L, LI H, et al. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study[J]. Lancet Infect Dis, 2021, 21(6):847-857. doi:  10.1016/S1473-3099(20)30596-X
[2] World Health Organization. Patient safety: making heathcare safe[EB/OL].(2017-11-6)[2023-04-20]. http://apps.who.int/iris/ handle/10665/255507.
[3] COBOS-VARGAS A, BUENO-CAVANILLAS A. Incident reporting. the weakest link in the patient safety systems[J]. Enferm Intensiva, 2024, 35(4):251-254. doi:  10.1016/j.enfi.2024.10.001
[4] SHOJANIA K G. Incident reporting systems: what will it take to make them less frustrating and achieve anything useful?[J]. Jt Comm J Qual Patient Saf, 2021, 47(12):755-758.
[5] LIU J J, ZHENG C R, HONG Y S, et al. How machine learning empowers management research-a comprehensive review of domestic and foreign frontiers and future prospects[J]. J Manag World, 2023, 39(9):191-216.
[6] NEZU M, SAKUMA M, NAKAMURA T, et al. Monitoring for adverse drug events of high-risk medications with a computerized clinical decision support system: a prospective cohort study[J]. Int J Qual Health Care, 2023, 35(4):mzad095. doi:  10.1093/intqhc/mzad095
[7] KNISELY B M, HATIM Q, VAUGHN-COOKE M. Utilizing deep learning for detecting adverse drug events in structured and unstructured regulatory drug data sets[J]. Pharmaceut Med, 2022, 36(5):307-317.
[8] 郭代红, 朱曼, 徐元杰等. 信息化军队药物警戒系统的构建与应用[J]. 解放军药学学报, 2023, 36(2):95-99. doi:  10.3969/j.issn.1008-9926.2023.02.001
[9]

MOHER D, LIBERATI A, TETZLAFF J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. PLoS Med, 2009, 6(7):e1000097. doi:  10.1371/journal.pmed.1000097
[10]

CLASSEN D C, PESTOTNIK S L, EVANS R S, et al. Computerized surveillance of adverse drug events in hospital patients[J]. JAMA, 1991, 266(20):2847-2851. doi:  10.1001/jama.1991.03470200059035
[11]

EVANS R S, PESTOTNIK S L, CLASSEN D C, et al. Development of a computerized adverse drug event monitor[J]. Proc Annu Symp Comput Appl Med Care, 1991: 23-27.
[12]

JHA A K, KUPERMAN G J, TEICH J M, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report[J]. J Am Med Inform Assoc, 1998, 5(3):305-314. doi:  10.1136/jamia.1998.0050305
[13]

AZAZ-LIVSHITS T, LEVY M, SADAN B, et al. Computerized survelliance of adverse drug reactions in hospital: pilot study[J]. Br J Clin Pharmacol, 1998, 45(3):309-314. doi:  10.1046/j.1365-2125.1998.00685.x
[14]

DORMANN H, MUTH-SELBACH U, KREBS S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting[J]. Drug Saf, 2000, 22(2):161-168. doi:  10.2165/00002018-200022020-00007
[15]

DORMANN H, CRIEGEE-RIECK M, NEUBERT A, et al. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology[J]. Aliment Pharmacol Ther, 2004, 19(3):303-309. doi:  10.1111/j.1365-2036.2004.01854.x
[16] 关丽英, 谢程. 我院从自动上报到主动监测质子泵抑制剂不良反应效果分析[J]. 中国药物应用与监测, 2021, 18(3):178-180. doi:  10.3969/j.issn.1672-8157.2021.03.010
[17] 杨继红, 姚帅君, 陈燕清, 等. 2002-2022 年生化汤研究文献可视化分析[J]. 中国中医药信息杂志, 2023, 30(10):75-80.
[18]

PATADIA V K, COLOMA P, SCHUEMIE M J, et al. Using real-world healthcare data for pharmacovigilance signal detection-the experience of the EU-ADR project[J]. Expert Rev Clin Pharmacol, 2015, 8(1):95-102. doi:  10.1586/17512433.2015.992878
[19] 郑晓琼. 美国FDA哨点系统5年战略规划(2019—2023年)[J]. 中国食品药品监管, 2020(3):81-98.
[20]

KANG M J, ALVARADO-GUZMAN J A, RASMUSSEN L V, et al. Evolution of a graph model for the OMOP common data model[J]. Appl Clin Inform, 2024, 15(5):1056-1065. doi:  10.1055/s-0044-1791487
[21] 白荷荷, 聂晓静, 夏丽, 等. 基于中国医院药物警戒系统开展药品不良反应监测的效果评价[J]. 中国药物警戒, 2022, 19(10):1136-1139.
[22]

KONG X H, GUO D H, LIU S Y, et al. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: a matched case-control study[J]. Br J Clin Pharmacol, 2021, 87(11):4304-4312. doi:  10.1111/bcp.14847
[23] 葛剑力, 张华. 药物不良事件监测系统在老年人群中的应用[J]. 国外医学(老年医学分册), 2009, 6:245-249.
[24] 马洁, 马瑞改, 白秋江. 基于 Apriori 算法的阿托伐他汀联合降压药相互作用不良反应高危因素的关联性分析[J]. 中国医院药学杂志, 2020, 40(18):1962-1967.
[25] 国家药品监督管理局药品评审中心. 国家药监局药审中心关于发布《用于产生真实世界证据的真实世界数据指导原则(试行)》的通告(2021年第27号)[EB/OL].(2021-04-13)[2021-08-07]. https://www.cde.org.cn/main/news/viewInfoCommon/2a1c437ed54e7b838a7e86f4ac21c539.
[26]

HUANG K, LIN F J, OU H T, et al. Building an active medical product safety surveillance system in Taiwan: Adaptation of the U. S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan[J]. Pharmacoepidemiol Drug Saf, 2021, 30(1):97-101. doi:  10.1002/pds.5168
[27]

CHEN C, JIA W P, GUO D H, et al. Development of a computer-assisted adverse drug events alarm and assessment system for hospital inpatients in China[J]. Ther Innov Regul Sci, 2020, 54(1):32-41. doi:  10.1007/s43441-019-00027-z
[28] 郭海丽, 郭代红, 朱曼, 等. 左氧氟沙星致心律失常的发生特点和危险因素分析[J]. 药物流行病学杂志, 2024, 33(1):37-44. doi:  10.12173/j.issn.1005-0698.202306038
[29]

RACHEL M S, JANE M H, KATHERINE S, et al. Emergency department programs to support medication safety in older adults: a systematic review and meta-analysis[J]. JAMA Netw Open, 2025, 8(3):e250814. doi:  10.1001/jamanetworkopen.2025.0814
[30]

HERSHEY L A. Avoiding adverse drug reactions in the elderly. Mt Sinai J Med, 1988, 55: 244–250.
[31]

PRAMOD K S, ARUP K M, AJAY G, et al. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence[J]. Indian J Pharmacol, 2018, 50(5):273-278. doi:  10.4103/ijp.IJP_544_17